SOURCE: Barrier Therapeutics, Inc.

October 22, 2007 07:30 ET

Barrier Therapeutics to Release Third Quarter 2007 Financial Results on October 30, 2007

Company to Host Conference Call on October 30, 2007 at 4:30 p.m. ET

PRINCETON, NJ--(Marketwire - October 22, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, will release third quarter 2007 financial results on Tuesday, October 30, 2007 at approximately 4:00 p.m. ET. The company will host a conference call that day at 4:30 p.m. ET to provide a company update and discuss the financial results for the quarter.

Conference call details:

Date:                 Tuesday, October 30, 2007
Time:                 4:30 p.m. ET
Dial-in:              866-831-6247 (U.S.)
                      617-213-8856 (International)
Conference ID code:   25693133
Web cast:   
                      (Investor Relations section)

An audio replay of the call will be available for seven days:

Access:               888-286-8010 (U.S.)
                      617-801-6888 (International)
                      Replay Passcode: 27284359

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel® (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at:

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    EVP & CFO
    (609) 945-1202

    Lazar Partners Ltd.
    Gregory Gin
    Investor Relations
    (212) 867-1762